SLC5A2 and Ventricular arrhythmia: Clinical trials using sacubitril-valsartan (ARNI) and sodium-glucose co-transporter 2 inhibitors (SGLT2) have demonstrated a consistent reduction in ventricular arrhythmias and SCD due to their anti-arrhythmic properties in addition to their ability to improve LVEF, thus reducing the eligibility for ICD implantation based on LVEF ≤35% (151–154).